1
PharmacoEconomics & Outcomes News 647 - 18 Feb 2012 Willing to pay to be skinny? Obese individuals place "a high value on weight loss and avoiding changes to their lifestyle, and less value on reducing long-term risks to health" say researchers from the UK and USA who reported the results of their study * in Obesity. An online survey was developed and completed by 502 obese patients attempting to lose weight in the UK and USA (n = 251 in both). The participants indicated their preference for hypothetical treatments which varied by seven attributes: long-term health risk reduction, percentage of weight loss, delivery mode, time to noticeable weight loss, side effects, lifestyle modification and costs. Weight loss of > 21kg and 28kg was deemed "acceptable" by participants in the UK and USA, respectively. Although all treatment attributes were important (p < 0.001) ** , percentage weight loss was seen as the most important factor. Participants in the UK and USA were willing to pay £6.51 and $US10.49 per month, respectively, for a hypothetical pharmacotherapy that resulted in a one percentage point reduction in bodyweight. Therapies that did not require substantial lifestyle modifications were highly valued, and participants were willing to pay £17.78 and $30.77 per month for a once-daily pill versus a weekly injection. * supported by Eli Lilly & Co ** with the exception of "time to noticeable weight loss" Doyle S, et al. Willingness to Pay for Obesity Pharmacotherapy. Obesity (Silver Spring, Md.) : 2 Feb 2012. Available from: URL: http://dx.doi.org/10.1038/ oby.2011.387 803066996 1 PharmacoEconomics & Outcomes News 18 Feb 2012 No. 647 1173-5503/10/0647-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved

Willing to pay to be skinny?

  • Upload
    trandat

  • View
    212

  • Download
    0

Embed Size (px)

Citation preview

Page 1: Willing to pay to be skinny?

PharmacoEconomics & Outcomes News 647 - 18 Feb 2012

Willing to pay to be skinny?Obese individuals place "a high value on weight loss

and avoiding changes to their lifestyle, and less value onreducing long-term risks to health" say researchers fromthe UK and USA who reported the results of their study*

in Obesity.An online survey was developed and completed by

502 obese patients attempting to lose weight in the UKand USA (n = 251 in both). The participants indicatedtheir preference for hypothetical treatments whichvaried by seven attributes: long-term health riskreduction, percentage of weight loss, delivery mode,time to noticeable weight loss, side effects, lifestylemodification and costs.

Weight loss of > 21kg and 28kg was deemed"acceptable" by participants in the UK and USA,respectively.

Although all treatment attributes were important(p < 0.001)**, percentage weight loss was seen as themost important factor. Participants in the UK and USAwere willing to pay £6.51 and $US10.49 per month,respectively, for a hypothetical pharmacotherapy thatresulted in a one percentage point reduction inbodyweight. Therapies that did not require substantiallifestyle modifications were highly valued, andparticipants were willing to pay £17.78 and $30.77 permonth for a once-daily pill versus a weekly injection.* supported by Eli Lilly & Co** with the exception of "time to noticeable weight loss"

Doyle S, et al. Willingness to Pay for Obesity Pharmacotherapy. Obesity (SilverSpring, Md.) : 2 Feb 2012. Available from: URL: http://dx.doi.org/10.1038/oby.2011.387 803066996

1

PharmacoEconomics & Outcomes News 18 Feb 2012 No. 6471173-5503/10/0647-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved